• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said the FDA extended the PDUFA date for Lymphoseek (99m-Tc-Tilmanocept) by 90 days, to Sept. 10, after the company provided updated chemistry, manufacturing and control information requested by the agency within the 90-day period prior to the original PDUFA date. Lymphoseek is a radioactive tracing agent for lymphatic mapping and lymphoscintigraphy.